



# The Impact of Artificial Intelligence Across Key Industries: Key Intermede Discussion Points

Intermede Investment Partners Limited



## INTERMEDE

INVESTMENT PARTNERS

a partner of



ASSET MANAGEMENT



# Contents

3	Introduction
3	Financial Services
4	Healthcare
5	Consumer, E-Commerce, and Online Travel Sectors
6	Industrials
7	Technology
7	Conclusion
9	Disclaimers

## Introduction

Artificial intelligence (AI) is rapidly reshaping the global economic landscape, with profound implications across multiple industries. In March 2026, Intermede Investment Partners held one of its periodic book review meetings, where the investment team share their perspective on a common text. This time, we read 'AI 2027', a paper by the AI Futures Project. Using their backgrounds in AI research and forecasting, the authors attempt to assess what a future with artificial general intelligence (AGI) might look like, amidst “frustratingly vague” accounts currently available. The (rather dystopian) scenario they come up with is, they say, intended to foster debate and elicit alternative views.

It was while we were reading this that the much discussed Citrini Research paper – The Global Intelligence Crisis - was released, along with the many counter-scenarios offered in its wake. Market movements aside, the most significant impact of the Citrini paper was to highlight just how little is known about what the impact of AGI might be – and how securities can be affected in response to any information filling that vacuum.

Within this context, we decided to use the AI 2027 paper, as well as other scenarios and essays released at the opening of 2026 to reflect on the impact that advanced AI, or AGI may have on the sectors we cover. While the very fact of the wide array of forecasts, scenarios and guesses shows that no one truly knows the likely impact, we felt this was a good starting point for challenging our views on key sectors we follow and invest in. Though there was ample debate about some of the scenarios explored by the authors, we stayed focused on exploring AI's transformative potential in the financial sector, healthcare, industrials, consumer-facing industries such as e-commerce and online travel, and the technology sector itself.

While AI offers significant opportunities for efficiency, innovation, and productivity gains, it also introduces substantial risks related to business model disruption, regulatory uncertainty, and macroeconomic instability. Intermede's analysts shared some insights into how AI could shape their industries, highlighting both near-term and long-term considerations.

Below is a brief overview of the discussion.

## Financial Services

The financial services sector—including banks, wealth managers, insurance firms, exchanges, and financial information providers—faces a complex and uneven AI-driven transformation. A primary opportunity for the application of AI in banking lies in the potential for operational efficiency gains and improved decision-making, although these gains will likely be at least partially shared with customers in what is a competitive market.

The core banking business model is currently relatively insulated from potential AI disruption due to regulatory constraints, and since AI cannot replicate the provision of balance sheet (taking deposits and issuing loans) which requires capital. Despite this stability, AI introduces notable risks to traditional revenue streams. For example, automated deposit optimisation tools may reduce the profitability banks derive from customer inertia.

Macroeconomic risks also loom large. For example, AI-driven unemployment could reduce consumer borrowing capacity and increase loan defaults, particularly affecting institutions with high exposure to retail lending. Credit card companies and banks heavily reliant on unsecured lending may therefore face heightened vulnerability. On the other hand, government intervention could mitigate these risks, reflecting the sector's close ties to public policy.

Regional variation further complicates the outlook. Faster AI adoption in the United States may drive efficiency gains, but also increase exposure to disruption. In contrast, European institutions may benefit from greater stability due to stricter labour protections, albeit at the cost of slower innovation.

Within adjacent financial industries, AI presents both commoditisation risks and data-driven opportunities. Wealth management may see fee compression as AI democratises financial advice, while insurance products could become more easily comparable, eroding pricing power. Derivative exchanges are likely to prove relatively resilient to AI disruption, whilst the impact on financial information providers will likely vary depending on the nature of the information provided (e.g. proprietary vs non-proprietary, analytical value add/benchmark status.)

## Healthcare

Healthcare represents a sector where AI adoption is expected to be gradual and phased, but also deeply transformative, particularly in administrative processes and pharmaceutical innovation. We expect the impact to unfold across three broad phases: near-term administrative efficiency, medium-term R&D productivity, and longer-term increases in scientific output and industry restructuring.

One of the most immediate benefits of AI lies in reducing administrative costs. Healthcare providers and insurers are investing heavily in automation to streamline operations, which could improve efficiency and reduce system-wide expenses. However, these gains may not translate into sustained profit expansion, as regulatory frameworks and payer dynamics often redirect cost savings toward consumers or governments, meaning value accrual is likely to favour scaled operators initially but be competed away over time.

In the pharmaceutical industry, AI holds significant promise for accelerating drug discovery and optimising clinical trials. AI also has the potential to improve probability of success and capital allocation across pipelines,

reinforcing advantages for scaled, data-rich organisations with diversified portfolios. Large, well-capitalised pharmaceutical companies are particularly well-positioned to leverage these capabilities, potentially strengthening their competitive advantage. Nevertheless, the long development cycles and stringent regulatory requirements in drug approval mean that meaningful returns on AI investments may take a decade or more to materialise. Smaller biotechnology firms could face increased competitive pressure as larger players rely less on acquiring pipeline drugs and instead invest more on internal research and development functions via AI tools. AI adoption is also likely to drive second-order effects across the ecosystem. In the near term, research budgets may shift toward computational capabilities, creating pressure on traditional research tools and services. However, over time the higher scientific output is likely to increase demand for experimentation, manufacturing, and diagnostics, resulting in more cyclicity rather than eliminating them.

From a risk perspective, the primary consideration is not whether AI improves productivity, but how much of that benefit can be captured economically and who captures it. In many parts of healthcare, efficiency gains are likely to be competed away or regulated, limiting sustained margin expansion. Those who can apply AI early may be able to capture low hanging fruit before competition arrives; however, adoption may also be slower than expected given regulatory, clinical, and workflow constraints which may ultimately even the playing field between incumbents and any would be disruptors. Regulatory oversight and intellectual property protections are likely to preserve the role of established pharmaceutical firms, even in scenarios involving highly advanced AI integration. Finally, concerns about bias, misinformation, and overreliance on AI tools present ethical and operational challenges, particularly in sensitive clinical contexts. These include concerns around data privacy, intellectual property protections, model bias, and the reliability of AI-driven clinical decision-making, particularly in sensitive patient contexts. In addition, patient and clinician hesitancy around relying on AI-derived advice may slow adoption, especially where trust and accountability are critical. Regulatory oversight is therefore likely to remain stringent.

## Consumer, E-Commerce, and Online Travel Sectors

The consumer sector, particularly e-commerce and online travel agencies (OTAs), faces a dynamic interplay between disruption and enhancement driven by AI.

In e-commerce, the bearish perspective centres on disintermediation. AI-powered agents could bypass traditional platforms by sourcing products directly from manufacturers and optimising logistics, thereby undermining platform-based business models and reducing reliance on digital advertising. This scenario poses a significant threat to dominant marketplace operators.

Conversely, the bullish case emphasises the resilience of established platforms. Consumer behaviour continues to favour trusted applications for transaction completion, and AI is currently being used to enhance personalisation, recommendation systems, and operational efficiency. Rather than displacing platforms, AI may strengthen their competitive positioning in the near term.

A similar dichotomy exists in the online travel sector. AI could enable direct booking between consumers and service providers, intensifying competition and compressing commission margins for intermediaries. However, OTAs may also leverage AI to improve user experience through better recommendations, dynamic pricing, and customer support. Platforms with differentiated offerings—such as unique inventory—are particularly well-positioned to maintain relevance.

Overall, while the long-term threat of disintermediation cannot be dismissed, current evidence suggests that AI is more likely to augment rather than replace these platforms in the near future.

## Industrials

The Industrials sector sits at the centre of the physical build-out required to enable AI, while facing a gradual and uneven adoption curve within its own operations. Long asset lifecycles, complex integration, and mission-critical applications mean change is likely to be evolutionary rather than disruptive.

A key opportunity lies in AI-driven infrastructure demand. Data centre expansion, electrification, and automation are driving incremental demand for electrical equipment, thermal management, power systems, and precision components, with power and cooling particularly well positioned. However, delivery is constrained by grid infrastructure — permitting delays and interconnection backlogs may defer demand — while supportive pricing is likely to attract new supply, creating risk of margin normalisation. Hyperscaler capex remains the key driver, and any change in perceived returns could slow spending and exacerbate overcapacity risk. Contract structures and protections are an important mitigant, while backlog trends, customer commitments, and order intake dynamics will be key indicators to monitor.

Operationally, AI is enabling incremental efficiency gains across manufacturing, while enhancing the value proposition Original Equipment Manufacturers (OEMs) can offer customers in asset-intensive end markets such as mining, trucking, and agriculture. The benefit is primarily economic: higher uptime, lower operating and input costs, and improved safety, reducing total cost of ownership. Adoption remains measured, however, constrained by upfront cost, integration complexity, and operating model change. OEM efforts to layer SaaS-style revenues onto connected equipment face similar friction, with pricing power for software overlays not yet proven. In

aerospace and defence, AI is being integrated into mission systems and sustainment, but regulatory and ethical constraints are likely to limit full autonomy and favour incremental deployment.

A key challenge is separating genuine AI exposure from narrative while maintaining capital allocation discipline. AI linkage is often overstated, and moves into adjacencies — including data centre power — can sit outside core competencies and carry execution risk, particularly where M&A drives elevated multiples. As a result, the sector is likely to bifurcate between companies with clear exposure to structural AI demand and those where it remains more aspirational, with execution, pricing, and returns discipline the key differentiators.

## Technology

Perhaps inevitably, AI is reshaping market dynamics most visibly at the present time in the sector that gave it birth – technology.

The team started by reviewing the key advantage that lies with “AI enablers,” including semiconductor manufacturers, hardware infrastructure providers, and hyperscalers. These companies form the backbone of AI development and are expected to benefit from sustained demand for computational power and data processing capabilities. As a result, they have become central to many investment portfolios.

However, this concentration introduces valuation risks. High expectations for future growth have led to elevated valuations, raising concerns about the return on investment for AI infrastructure spending. Market scepticism persists as to whether current levels of capital expenditure will generate sufficient long-term returns.

Service-oriented and software companies face a different set of challenges. AI-driven automation and disintermediation could erode their value propositions, particularly for firms reliant on standardised processes. Nevertheless, companies with strong proprietary data, established customer relationships, and a commitment to innovation have the opportunity to transform their own businesses to win in the AI race.

## Conclusion

The discussion at Intermede highlighted the limitations of scenario-based forecasting. While extreme AI scenarios can be useful for stress-testing assumptions, they often reflect cultural and geopolitical biases—particularly an American-centric perspective—and may not translate into actionable investment insights. A more pragmatic approach focuses on medium-term productivity gains and incremental adoption.

Ultimately, our analysis underscores the importance of nuanced, industry-specific evaluation. Rather than relying on extreme scenarios, investors might need to focus on tangible, intermediate-term developments while remaining attentive to evolving risks. AI is unlikely to produce uniform outcomes; instead, its effects will vary significantly across sectors, firms, and geographies, shaping a complex and uneven economic transformation.

Finally, the team also spent time on discussing ethics, policy responses, and the role of long-term responsible investors like Intermede in this rapidly changing landscape. Whilst definitive investment conclusions remain elusive, our team did emphasise the importance of staying grounded in long-term thinking, pragmatic modelling, and responsible investment principles.

# Disclaimers

## GENERAL INFORMATION

This document has been produced by Intermede Investment Partners Limited ("Intermede"), a limited company registered in England and Wales (Reg. No. 8827481), having its registered office at 6 Warwick Street, London W1B 5LU, United Kingdom. Intermede is authorised and regulated by the UK Financial Conduct Authority with firm reference number: 624278. Intermede is registered as an Investment Adviser with the Securities and Exchange Commission in the United States.

This document has been provided for information purposes only and has not been provided as either a solicitation or recommendation with respect to the purchase or sale of any securities or an offer to provide investment services. The information contained in this document does not constitute an offer to purchase securities to any person in the United States or to any U.S. Person as such term is defined under the United States Securities Act of 1933, as amended.

The information provided is believed to be accurate at the time of compilation and is provided by Intermede in good faith. However, no representation is made or implied as to the quality, accuracy, reliability, timeliness or completeness of the material. Forward-looking statements reflect our views and assumptions with respect to future events as of the date of this document and are subject to risks and uncertainties. Given such uncertainties, undue reliance should not be placed on any forward-looking statements. Any opinions or estimates expressed are our current opinion as of the date of this document and are subject to change without notice. Except in so far as liability under any statute cannot be excluded, Intermede, its directors, employees, representatives and consultants do not accept and disclaim any liability (whether arising in contract, tort, negligence or otherwise) for any error or omission in the material or for any loss of damage (whether direct, indirect or consequential) that may be suffered by you, the recipient of the information, an investor or any other person. Certain information contained herein has been obtained from third-party sources and such information has not been independently verified by Intermede. No representation is made as to the accuracy or completeness of such information. Index performance and statistics are provided for comparison purposes only. They are not meant to be indicative of Intermede portfolio performance, asset composition, volatility, or other attributes, which will differ significantly from those of the index. Index returns do not take into account transaction costs or other fees and expenses. It is not possible to invest directly in an index.

The information contained in this document is not intended to be and should not be taken as investment, tax, legal or any other type of advice. It does not take into account the objectives, financial, tax or legal situation or needs of any investor or purport to be comprehensive and should not be relied upon as such. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on this document.

**This document is not intended for and is not to be distributed to retail investors.**

Intermede Investment Partners Ltd claims compliance with the Global Investment Performance Standards (GIPS®). Copies of all GIPS® composites is available on request. GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

Rates of return are for illustrative purposes only, with dividends reinvested and are net of fees and other expenses. Past performance is not a reliable indication of future performance, does not guarantee future results and all investments are subject to the risk of loss. As with all investments, income may fluctuate, values may fall as well as rise with changes in the market and an investor may not get back the amount invested. Income from investments may fluctuate. An investment with Intermede is not a deposit or liability and is not guaranteed by Intermede, its shareholders or employees or any affiliate. All information is to be treated as confidential and may not be reproduced or redistributed in whole or in part in any manner without the prior written consent of Intermede. This document is not intended for public use or distribution.

This information is issued and approved by Intermede, part of the Insignia Financial Ltd group of companies (comprising Insignia Financial Ltd ABN 49 100 103 722 and its related bodies corporate) ("Insignia Group").

The capital value, payment of income and performance of any investment with Intermede is not guaranteed. An investment with Intermede is subject to investment risk, including possible delays in repayment of capital and loss of income and principal invested.

Copyright © 2026 Intermede and/or its affiliates. All rights reserved

## UNITED KINGDOM

This document is directed only at persons in the United Kingdom who are professional clients within the meaning of Directive 2004/39/EC. Persons who do not have professional experience in matters relating to investments should not rely on this document.

## AUSTRALIA

In Australia, this information is solely for the use of persons who are "wholesale clients" (as defined in the Corporations Act 2001 (Cth)), which include (but are not limited to): (a) Australian financial services licensees, including but not limited to research report providers and financial advisers; (b) registrable superannuation entities; (c) a person or entity who controls gross assets of at least \$10 million; or (d) a person or entity that has obtained a qualified accountant's certificate (within the last 6 months) stating they have net assets of at least \$2.5 million, or a gross income for each of the last two financial years of at least \$250,000. This document must not be distributed to "retail clients" (as defined in the Corporations Act 2001 (Cth)). This document is not intended to be distributed or passed on, directly or indirectly, to any other class of persons in Australia.

Intermede Investment Partners Limited is exempt from the requirement to hold an Australian financial services licence under the Corporations Act in respect of the

financial services it provides. Intermede Investment Partners Limited is regulated by the FCA under United Kingdom laws, which differ from Australian laws.

This document is approved and distributed in Australia by MLC Asset Management Pty Limited ABN 44 106 427 472, AFSL No. 308953.

This document contains general information and may constitute general advice. Any advice in this communication has been prepared without taking account of individual objectives, financial situation or needs. It should not be relied upon as a substitute for financial or other specialist advice.

Before making any decisions on the basis of this document, you should consider the appropriateness of its content having regard to your particular investment objectives, financial situation or individual needs.

None of MLC Asset Management Pty Limited, MLC Asset Management Holdings Limited ABN 16 134 158 517 nor any other member company in the Insignia Group accepts any liability for or provides any guarantee in respect of the activities of Intermede.

The capital value, payment of income and performance of any financial product referred to in this document or an investment in any product offered by Intermede or any other member of the Insignia Group is not guaranteed. An investment in any such financial product is subject to investment risk, including possible delays in repayment of capital and loss of income and principal invested. Portfolio information provided in this presentation relates to a composite portfolio made up of all client portfolios managed by Intermede over the period or at the date specified and is not indicative or a guarantee of the composition of any portfolios managed by Intermede.

## NEW ZEALAND

In New Zealand, this information is solely for the use of researchers, financial advisers and wholesale clients. This material has been prepared without taking into account a potential investor's objectives, financial situation or needs and is not intended to constitute personal financial advice and must not be relied on as such. Recipients of this document, who are not wholesale investors (in accordance with Schedule 1, Clause 3 Financial Markets Conduct Act 2013), or their duly appointed agent, should consult an Authorised Financial Adviser and the relevant Product Disclosure Statement where applicable.

## UNITED STATES

This document is intended only for an investor that is a "qualified purchaser" as defined in the US Investment Company Act of 1940 and is not intended for public use or distribution. It is not to be construed as investment advice.

This material has been prepared as, and is furnished solely in connection with, a one-on-one presentation by Intermede and is not for public distribution. It is not to be construed as investment advice. This document is directed only at persons "in the United States" as defined by the United States Securities Act of 1933, as amended (the "US Securities Act"). This document is not to be distributed to any investor that is not a "qualified purchaser" as defined by the United States Investment Company Act of 1940 ("US Company Act").

Rates of return and other assumptions are for illustrative purposes only, with dividends reinvested and are net of fees and expenses. As an example, an account with an initial \$1,000,000 investment on January 1st, 2019, earning a recurring 2.4125% quarterly gross return (10.00% annualized), and paying a 0.20% quarterly management fee (0.80% annual fee) based on end of periods assets, would have grown to \$1,610,510 on a gross of fees basis and \$1,547,640 on a net of fees basis by December 31st, 2023 (5 years). Actual return and performance may vary significantly from the illustration and examples given.

This material has also included the application of potential market return based in part by historical market data. Thus, the potential effect of future market risk is not taken into account. There is no guarantee that the intended projections or results will be achieved. Past performance does not guarantee future results and may differ for different time periods. All investments are subject to the risk of loss.

Values may fall as well as rise and you may not get back the amount you invested. Income from investments may fluctuate. Certain information contained herein has been obtained from third-party sources and such information has not been independently verified by Intermede. No representation is made as to the accuracy or completeness of such information. Index performance and statistics are provided for comparison purposes only and relate to the MSCI ACWI, a market capitalization weighted index designed to provide a broad measure of equity-market performance throughout the world. The index is maintained by Morgan Stanley Capital International (MSCI) and is comprised of stocks from both developed and emerging markets. They are not meant to be indicative of Intermede portfolio performance, asset composition, volatility, or other attributes, which will differ significantly from those of the index. Index returns do not take into account transaction costs or other fees and expenses. It is not possible to invest directly in an index.

## OTHER COUNTRIES

The distribution of this document into any other jurisdictions may be restricted and accordingly any persons in such jurisdictions into whose possession this document comes are required to inform themselves about and to observe such restrictions.